The VMAT2 inhibitor failed to meet the primary end point in the ARTISTS 1 and ARTISTS 2 trials in the treatment of tics in pediatric patients with Tourette syndrome.
from Front page feed https://ift.tt/2PMnlGm
from Front page feed https://ift.tt/2PMnlGm
Comments
Post a Comment